A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 227 participants.

Also called NCT06716203

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 227 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06716203
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06716203. Randomized; double masking; primary purpose treatment. Start 2025-01-03 (actual); primary completion 2026-08-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Drug: 5 mg BGM0504 Administered SC
Intervention (Drug)
Drug: : 10 mg BGM0504 Administered SC
Intervention (Drug)
Drug: Placebo Administered SC
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd. (class: industry)
Collaborator
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06716203
Content hash
ebc78cc4d86b48a36c4e997d09d82cb280c2eef598a815ab9bc94e0b0ff8941a